A recent shift in the drug product environment for Africa has seen a score of new products being developed specifically for diseases of the developing world, creating new challenges for regulators in Africa and elsewhere.
Forfeiting our commons
The Lancet’s Series on Maternal and Child Undernutrition
President Obama's grand climate plan does not add up
Climate change can no longer be ignored
NGO demands withdrawal of Niyamgiri gram sabha notificatio
